Intersect plugs positive drug-eluting sinus implant data

Intersect ENT showed it has another device to add to its line of sinus implants, touting positive data from a pilot study of its new steroid delivery implant to treat chronic sinusitis. The quarter-sized device--placed during a physician's office visit rather than surgically--reduced ethmoid sinus obstruction from 66% to 21% and sustained that level for all 6 months of the study, the company said, eliminating the need for surgery in 64% of the patients. It's similar to Intersect's Propel model implants, but the new device has more radial strength and a longer drug-eluting period. The company announced the results at the Annual American Rhinologic Society Meeting in Vancouver, Canada. Earlier this year, Intersect pulled in a $30 million round of financing to support commercial expansion of its implants. Release

Suggested Articles

J&J launched a virtual clinical study to gauge whether Apple’s iPhone and ECG-enabled smartwatch can help reduce the risk of stroke and catch AFib.

The Salt Lake City-based developer said its Logix Smart test is now available to be exported from Utah to countries requiring the CE Mark.

Dexcom received a new European approval for its wearable continuous glucose monitor in pregnant women across Type 1, Type 2 and gestational diabetes.